Role of cytokines in the pathogenesis of acute and chronic kidney disease, glomerulonephritis, and end-stage kidney disease

References

• Jaber B, Rao M, Guo D, et al. Cytokine gene promoter polymorphisms and mortality in acute renal failure. Cytokine. 2004;25(5):212–219.
   PubMed Web of Science ®Google Scholar
• Carrero J, Park S, Axelsson J, Lindholm B, Stenvinkel P. Cytokines, atherogenesis, and hypercatabolism in chronic kidney disease: a dreadful triad. Semin Dialys. 2009;22(4):381–386.
   Web of Science ®Google Scholar
• Stenvinkel P, Ketteler M, Johnson R, et al. IL-10,IL-6, and TNF-α: central factors in the altered cytokine network of uremia. The good, the bad, and the ugly. Kidney Int. 2005;67:1216–1233.
   PubMed Web of Science ®Google Scholar
• Caglar K, Peng Y, Pupim LB, et al. Inflammatory signals associated with hemodialysis. Kidney Int. 2002;62:1408–1416.
   PubMed Web of Science ®Google Scholar
• Schindler R, Krautzig S, Lufft V et al. Induction of interleukin-1 and interleukin-1 receptor antagonist during contaminated in vitro dialysis with white whole blood. Nephrol Dial Transplant. 1996;11:101–108.
   Web of Science ®Google Scholar
• Descamps-Latscha B, Herbelin A, Nguyen AT, et al. Balance between IL-1-β, TNF-a, and their specific inhibitors in chronic renal failure and maintenance dialysis. J Immunol. 1995;154:882–892.
   PubMed Web of Science ®Google Scholar
• Girndt M, Kohler H, Schiedhelm-Weick E, et al. Production of interleukin-6, tumor necrosis factor alpha, and interleukin-10 in vitro correlates with the clinical immune defect in chronic hemodialysis patients. Kidney Int. 1995;47:559–565.
   PubMed Web of Science ®Google Scholar
• Nonner JC, Brody AR. Cytokine-binding proteins in the lung. Am J Physiol. 1995;268:L869–L878.
   Google Scholar
• Nash K, Hafeez A, Hou S. Hospital-acquired renal insufficiency. Am J Kidney Dis. 2002;39:930–936.
   PubMed Web of Science ®Google Scholar
• Kelly KJ, Molitoris BA. Acute renal failure in the new millennium: time to consider combination therapy. Semin Nephrol. 2000;20:4–19.
   PubMed Web of Science ®Google Scholar
• Vijayan A, Miller SB. Acute renal failure: prevention and non-dialytic therapy. Semin Nephrol. 1998;18:523–532.
   Web of Science ®Google Scholar
• Liano F, Junco E, Pascual J, Madero R, Verde E. The spectrum of acute renal failure in the intensive care unit compared with that seen in other settings. The Madrid Acute Renal Failure Study Group. Kidney Int Suppl. 1998;66:S16–S24.
   PubMedGoogle Scholar
• Sutton T, Fisher C, Molitoris B. Microvascular endothelial injury and dysfunction during ischemic acute renal failure. Kidney Int. 2002;62:1539–1549.
   PubMed Web of Science ®Google Scholar
• Hack CE, Zeerleder S. The endothelium in sepsis: source of and target for inflammation. Crit Care Med. 2001;29 Suppl 7:S21–S27.
   Google Scholar
• Ashworth SL, Molitoris BA. Pathophysiology and functional significance of apical membrane disruption during ischemia. Opin Nephrol Hypertens. 1999;8:449–458.
   PubMed Web of Science ®Google Scholar
• Star RA. Treatment of acute renal failure. Kidney Int. 1998;54:1817–1831.
   PubMed Web of Science ®Google Scholar
• Donnahoo KK, Meldrum DR, Shenkar R, et al. Early renal ischemia, with or without reperfusion, activates NF-kappaB and increases TNF-alpha bioactivity in the kidney. J Urol. 2000;163:1328–1332.
   PubMed Web of Science ®Google Scholar
• Kelly KJ, Plotkin Z, Dagher PC. Guanosine supplementation reduces apoptosis and protects renal function in the setting of ischemic injury. J Clin Invest. 2001;108:1291–1298.
   PubMed Web of Science ®Google Scholar
• Donnahoo KK, Meng X, Ayala A, et al. Early kidney TNF-alpha expression mediates neutrophil infiltration and injury after renal ischemia-reperfusion. Am J Physiol. 1999;277:R922–R929.
   PubMed Web of Science ®Google Scholar
• Ysebaert DK, de Greef KE, Vercauteren SR, et al. Identification and kinetics of leukocytes after severe ischemia/reperfusion renal injury. Nephrol Dial Transplant. 2000;15:1562–1574.
   PubMed Web of Science ®Google Scholar
• Willinger CC, Schramer H, Pfaller K, Pfaller W. Tissue distribution of neutrophils in postischemic acute renal failure. Virchows Arch B Cell Pathol Incl Mol Pathol. 1992;62:237–243.
   PubMedGoogle Scholar
• Schena FP Role of growth factors in acute renal failure. Kidney Int Suppl. 1998;66:S11–S15.
   Google Scholar
• Burne MJ, Daniels F, El Ghandour A, et al. Identification of the CD4(+) T cell as a mayor pathogenic factor in ischemic acute renal failure. J Clin Invest. 2001;108:1283–1290.
   PubMed Web of Science ®Google Scholar
• Park P, Haas M, Cunningham PN, et al. Injury in renal ischemia-reperfusion is independent from immunoglobulins and T lymphocytes. Am J Physiol (Renal Physiol). 2002;282:F352–F357.
   Web of Science ®Google Scholar
• Molitoris BA, Marrs J. The role of cell adhesion molecules in ischemic acute renal failure. Am J Med. 1999;106:583–592.
   PubMed Web of Science ®Google Scholar
• Ichikawa H, Flores S, Kvietys PR, et al. Molecular mechanisms of anoxia/reoxygenation-induced neutrophil adherence to cultures endothelial cells. Cir Res. 1997;81:922–931.
   PubMed Web of Science ®Google Scholar
• Okusa MD, Linden J, Hunag L, et al. Enhanced protection from renal ischemia: reperfusion injury with A(2A)-adenosine receptor activation and PDE 4 inhibition. Kidney Int. 2001;59:2114–2125.
   PubMed Web of Science ®Google Scholar
• Cunningham P, Dyanov H, Park P, Wang J, Newell K, Quigg R. Acute renal failure in endotoxemia is caused by TNF acting directly on TNF receptor-1 in kidney. J Immunol. 2002;168(11):5817–5823.
   PubMed Web of Science ®Google Scholar
• Van Deventer S, Buller S, ten Cate J, Arden A, Hack C, Sturk A. Experimental endotoxemia in humans: analysis of cytokine release and coagulation, fibrinolytic, and complement pathways. Blood. 1990;76(12):2520–2526.
   PubMed Web of Science ®Google Scholar
• Peschon J, Torrance K, Stocking M, et al. TNF receptor-deficient mice reveal divergent roles for p55 and p75 in several models of inflammation. J Immunol. 1998;160(2):943–952.
   Web of Science ®Google Scholar
• Maier S, Emmanuilidis M, Entleutner N, et al. Massive chemokine transcription in acute renal failure due to polymicrobial sepsis. Shock. 2000;14(2):187–192.
   Web of Science ®Google Scholar
• Cohen J, Carlet J. INTERSEPT: an international, multicenter, placebo-controlled trial of monoclonal antibody to human tumor necrosis factor-α in patients with sepsis. Crit Care Med. 1996;24(9):1431–1440.
   PubMed Web of Science ®Google Scholar
• Merouani A, Shpall E, Jones R, Archer PG, Schrier RW. Renal function in high dose chemotherapy and autologous hematopoietic cell support treatment for breast cancer. Kidney Int. 1996;50(3):1026–1031.
   PubMed Web of Science ®Google Scholar
• Deng J, KhondaY, Chiao H, et al. Interleukin-10 inhibits ischemic and cisplatin-induced acute renal failure injury. Kidney Int. 2001;60(6):2118–2128.
   Web of Science ®Google Scholar
• Kelly KJ, Meehan SM, Colvin RB, Williams WW, Bonventre JV. Protection from toxicant-mediated renal injury in the rat with anti-CD54 antibody. Kidney Int. 1999;56(3):922–931.
   Web of Science ®Google Scholar
• Pinckard JK, Sheehan KC, Schreiber RD. Ligand-induced formation of the p55 and p75 tumor necrosis factor receptor heterocomplex on intact cells. J Biol Chem. 1997;272:10784–10789.
   Web of Science ®Google Scholar
• Yuan M, Konstantopoulos N, Lee J, et al. Reversal of obesity-and diet-induced insulin resistance with salicylate or targeted disruption of Ikkβ. Science. 2001;293(5535):1673–1677.
   PubMed Web of Science ®Google Scholar
• Ramesh G, Reeves W. Inflammatory cytokines in acute renal failure. Kidney Int. 2004;66:S56–S61.
   Web of Science ®Google Scholar
• Crawel E, Kay R, Sillibourne J, Patel P, Hutchinson I, Woo P. Polymorphic haplotypes of the interleukin-10 5’ flanking region determine variable interleukin-10 transcription and are associated with particular phenotypes ofjuvenile rheumatoid arthritis. Arthritis Rheum. 1999;42:1101–1108.
   Google Scholar
• Mira JP, Cariou A, Grali F, et al. Association of TNF-2, a TNF-(alpha) promoter polymorphism with septic shock susceptibility and mortality: a multicenter study. JAMA. 1999;282(6):561–568.
   PubMed Web of Science ®Google Scholar
• Oberholzer A, Oberholzer C, Moldawer L. Interleukin-10: a complex role in the pathogenesis of sepsis syndromes and its potential as an anti-inflammatory drug. Crit Care Med. 2002;30 Suppl 1:S58–S63.
   Google Scholar
• Van Der Poll T, Jansen J, Levi M, ten Cate H, ten Cate JW van Deventer SJ. Regulation of interleukin 10 release by tumor necrosis factor in humans and chimpanzees. J Exp Med. 1994;180(5):1985–1988.
   PubMed Web of Science ®Google Scholar
• Cox ED, Hoffmann SC, DiMercurio BS, et al. Cytokine polymorphisms analyses indicate ethnic differences in the allelic distribution of interleukin-2 and interleukin-6. Transplantation. 2001;72(4):720–726.
   Web of Science ®Google Scholar
• Simmons EM, Himmelfarb J, Sezer MT, et al. Plasma cytokine levels predict mortality in patients with acute renal failure. Kidney Int. 2004;65(4):1357–1365.
   PubMed Web of Science ®Google Scholar
• Bone RC, Grodzin CJ, Balk RA. Sepsis: a new hypothesis for pathogenesis of the disease process. Chest. 1997;112(1):235–243.
   Web of Science ®Google Scholar
• Gogos CA, Drosou E, Bassaris HP, SkoutelisA. Pro-versus anti-inflammatory cytokine profile in patients with severe sepsis: A marker for prognosis and future therapeutic options. J Infect Dis. 2000;181(1):176–180.
   PubMed Web of Science ®Google Scholar
• Okusawa S, Gelfand JA, Ikejima T, Connelly RJ, Dinarello CA. Interleukin 1 induces a shock-like state in rabbits. Synergism with tumor necrosis factor and the effect of cyclooxygenase inhibition. J Clin Invest. 1988;81(4):107–114.
   Web of Science ®Google Scholar
• Friedman G, Jankowski S, Marchant A, Goldman M, Kahn RJ, Vincent JL. Blood interleukin 10 levels parallel the severity of septic shock. J Crit Care. 1997;12(4):183–187.
   PubMed Web of Science ®Google Scholar
• Sfeir T, Saha DC, Astiz M, Rackow A. Role of interleukin-10 in monocyte hyporesponsiveness associated with septic shock. Crit Care Med. 2001;29(1):129–133.
   Web of Science ®Google Scholar
• Torre-Amione G, Kapadia S, Benedict C, Oral H, Young JB, Mann DL. Proinflammatory cytokine levels in patients with depressed left ventricular ejection fraction: a report from the Studies of Left Ventricular Dysfunction (SOLVD). J Am Coll Cardiol. 1996;27(5):1201–1206.
   PubMed Web of Science ®Google Scholar
• Ertel W, Kremer JP, Kenney J, et al. Downregulation of proinflammatory cytokine release in whole blood from septic patients. Blood. 1995;85(5):1341–1347.
   PubMed Web of Science ®Google Scholar
• Paust HK, Turner JE, Steinmetz OM, et al. The interleukin-23/Th17 axis contributes to renal injury in experimental glomeruloneophritis. J Am Soc Nephrol. 2009;20:969–979.
   PubMed Web of Science ®Google Scholar
• Kurts C, Heymann F, Lukacs-Koornek V, Foege J. Role of T cells and dendritic cells in glomerular immunopathology. Semin Immunopathol. 2007;29:317–335.
   Web of Science ®Google Scholar
• Tipping PG, Holdsworth SR. T cells in crescentic glomerulonephritis. J Am Soc Nephrol. 2006;17:1253–1263.
   PubMed Web of Science ®Google Scholar
• Kitching AR, Turner AL, Wilson GR, et al. IL-12p40 and IL-18 in crescentic glomerulonephritis: IL-12p40 is the key Th1-defining cytokine chain, whereas IL-18 promotes local inflammation and leukocyte recruitment. J Am Soc Nephrol. 2005;16(7):2023–2033.
   PubMed Web of Science ®Google Scholar
• Huang XR, Tipping PG, Shuo L, Holdsworth SR. Th1 responsiveness to nephritogenic antigens determines susceptibility to crescentic glomerulonephritis in mice. Kidney Int. 1997;51:94–103.
   Web of Science ®Google Scholar
• Mu W, Ouyang X, Agarwal A, et al. Il-10 suppresses chemokines, inflammation, and fibrosis in a model of chronic renal disease. J Am Soc Nephrol. 2005;16(12):3651–3660.
   Web of Science ®Google Scholar
• Segerer S, Schlondorff D. Role of chemokines for the localization of leukocyte subsets in the kidney. Semin Nephrol. 2007;27:260–274.
   Web of Science ®Google Scholar
• Woltman AM, de Haij S, Boonstra JG, Gobin SJ, Daha MR, van Kooten C. Interleukin-17 and CD40-ligand synergistically enhance cytokine and chemokine production by renal epithelial cells. J Am Soc Nephrol. 2000;11:2044–2055.
   PubMed Web of Science ®Google Scholar
• United Kingdom Prospective Diabetes Study (UKPDS) Group. Intensive blood-glucose control with sulphonylureas or insulin compared with conventional treatment and risks of complications in patients with type 2 diabetes (UKPDS 33). Lancet. 1998;352:837–853.
   PubMed Web of Science ®Google Scholar
• Hill C, Flyvbjerg A, Grønbæk, et al. The renal expression of transforming growth factor β isoforms and their receptors in acute and chronic experimental diabetes in rats. Endocrinology. 2000;141(3):1196–1208.
   Web of Science ®Google Scholar
• Roberts AB, McCune BK, Sporn MB. TGF-β-1: regulation of extracellular matrix. Kidney Int. 1992;41:557–559.
   PubMed Web of Science ®Google Scholar
• Marti HP, Lee L, Kashgarian M, Lovett DH. Transforming growth factor β1 stimulates mesangial cell synthesis of the 72-kD type IV collagenase. Am J Pathol. 1994;144;82–94.
   Web of Science ®Google Scholar
• Nakamura T, Fukui M, Ebihara E, et al. mRNA expression of growth factors in glomeruli from diabetic rats. Diabetes. 1993;42(3):450–456.
   PubMed Web of Science ®Google Scholar
• Kolm V Sauer U, Olgemoller B, Schleicher ED. High glucose-induced TGF-β1 regulates mesangial production of heparin sulphate proteoglycan. Am J Physiol. 1996;70(5):F812–F821.
   Google Scholar
• Shankland SJ, Scholey JW. Expression of transforming growth factor p1 during diabetic renal hypertrophy. Kidney Int. 1994;46:430–442.
   PubMed Web of Science ®Google Scholar
• Wrana JL, Attisano L, Wieser R, Ventura F, Massague J. Mechanisms of activation of the TGF-β receptor. Nature. 1994;370:341–347.
   PubMed Web of Science ®Google Scholar
• Kagami S, Border WA, Miller DE, Noble NA. Angiotensin II stimulates extracellular matrix protein synthesis through induction of transforming growth factor-β expression in rat glomerular mesangial cells. J Clin Invest. 1994;93:2431–2437.
   PubMed Web of Science ®Google Scholar
• Guh JY, Yang ML, Yang YL, Chang CC, Chuang LY. Captopril reverses high-glucose induced growth effects on LLC-PK1 cells partly by decreasing transforming growth factor-β receptor protein expression. J Am Soc Nephrol. 1996;7:1207–1215.
   Web of Science ®Google Scholar
• Flyvbjerg A, Hill C, Grønbæk H, Logan A. Effects of ACE-inhibition on renal TGF-β type II receptor expression in experimental diabetes in rats [abstract]. J Am Soc Nephrol. 1999;10:A3444.
   Google Scholar
• Esposito K, Marfella R, Giugliano D. Plasma interleukin-18 concentrations are elevated in type 2 diabetes. Diabetes Care. 2004;27(1):272.
   Web of Science ®Google Scholar
• Esposito K, Nappo F, Marfella R, et al. Inflammatory cytokine concentrations are acutely increased by hyperglycemia in humans: role of oxidative stress. Circulation. 2002;106(16):2067–2072.
   PubMed Web of Science ®Google Scholar
• Okada S, Shikata K, Matsuda M, et al. Intercellular adhesion molecule-1-deficient mice are resistant against renal injury after induction of diabetes. Diabetes. 2003;52(10):2586–2593.
   Web of Science ®Google Scholar
• Schwartz M, Wahl M, Resch K, Radeke HH. IFN gamma induces functional chemokine receptor expression in human mesangial cells. Clin Exp Immunol. 2002;128:285–294.
   Web of Science ®Google Scholar
• Dai SM, Matsuno H, Nakamura H, Nishioka K, Yudoh K. Interleukin-18 enhances monocyte tumor necrosis factor alpha and interleukin-1beta production induced by direct contact with T-lymphocytes: implications in rheumatoid arthritis. Arthitis Rheum. 2004;50(2):432–443.
   Google Scholar
• Nakamura A, Shikata K, Hiramatsu T, et al. Serum interleukin -18 levels are associated with nephropathy and atherosclerosis in Japanese patients with type 2 diabetes. Diabetes Care. 2005;28(12):2890–2895.
   Web of Science ®Google Scholar
• Broyer M, Meyrier A, Niaudet P, Habbib R. Minimal changes and focal segmental glomerulosclerosis. In: Davison AM, Cameron SJ, Grunfeld JP, Kerr D, Ritz E, editors. Oxford Textbook of Clinical Nephrology, Vol 3. 1st ed. Oxford: Oxford University Press; 1992:299–339.
   Google Scholar
• Parry RG, Gillespie KM, Parnham A, Clark GB, Mathieson PW. Interleukin-4 and interleukin-4 receptor polymorphisms in minimal change nephropathy. Clin Sci(Lond). 1999:96:665–668.
   Web of Science ®Google Scholar
• Lai KW, Wei CL, Tan LK, et al. Over expression of interleukin-13 induces minimal change-like nephropathy in rats. J Am Soc Nephrol. 2007;18(5):1476–1485.
   Web of Science ®Google Scholar
• Cheung W, Wei CL, Seah CC, Jordan SC, Yap HK. Atopy, serum IgE, and interleukin-13 in steroid-responsive nephritic syndrome. Pediatr Nephrol. 2004;19(6):627–632.
   Web of Science ®Google Scholar
• Van Den Berg JG, Aten J, Chand MA, et al. Interleukin-4 and interleukin-13 act on glomerular visceral epithelial cells. J Am Soc Nephrol. 2000;11(3):413–422.
   Web of Science ®Google Scholar
• Reiser J, von Gersdorff G, Loos M, et al. Induction of B7–1 in podocytes is associated with nephrotic syndrome. J Clin Invest. 2004;113(10):1390–1397.
   PubMed Web of Science ®Google Scholar
• Garin EH, Diaz L, Mu W, Araya CE, Johnson RJ. Urinary CD80 excretion is increased in idiopathic minimal lesion nephrotic syndrome. J Am Soc Nephrol. 2009;20:260–266.
   PubMed Web of Science ®Google Scholar
• Syrjanen J, Hurme M, Lehtimaki T, Mustonen J, Pasternack A. Polymorphism of the cytokine genes and IgA nephropathy. Kidney Int. 2002;61(3):1079–1085.
   Web of Science ®Google Scholar
• Rantal I, Mustonen J, Hurme M, et al. Pathogenetic aspects of IgA nephropathy. Nephron. 2001;88:193–198.
   Web of Science ®Google Scholar
• Shu KH, Lee SH, Cheng CH, et al. Impact of interleukin- 1 receptor antagonist and tumor necrosis factor-alpha gene polymorphism on IgA nephropathy. Kidney Int. 2000;58:783–789.
   PubMed Web of Science ®Google Scholar
• Yano N, Endoh M, Nomoto Y, Sakai H, Fadden K, Rifai A. Phenotypic characterization of cytokine expression in patients with IgA nephropathy, J Clin Immunol. 1997;17(5)396–403.
   Web of Science ®Google Scholar
• Mezzano SA, Droguett MA, Burgos E, et al. Overexpression of chemokines, fibrogenic cytokines, and myofibroblasts in human membranous nephropathy. Kidney Int. 2000;57:147–158.
   PubMed Web of Science ®Google Scholar
• Abbate M, Zoja C, Corna D, Capitano M, Bertani T, Remuzzi G. In progressive nephropathies, overload of tubular cells with filtered proteins translates glomerular permeability dysfunction into cellular signals of interstitial inflammation. J Am Soc Nephrol. 1998;9(7):1213–1224.
   Web of Science ®Google Scholar
• Pichler R, Giachelli CM, Lombardi D, et al. Tubulointerstitial disease in glomerulonephritis: potential role of osteopontin (uropontin). Am J Pathol. 1994:144(5):915–926.
   Web of Science ®Google Scholar
• Bantis C, Heering PJ, Luther Y, et al. Influence of cytokine gene polymorphisms in focal segmental glomerulosclerosis. Am J Nephrol. 2004;24:427–431.
   Web of Science ®Google Scholar
• Grassl C, Luckow B, Schlondorff D, Dendorfer U. Transcriptional regulation of the interleukin-6 gene in mesangial cells. J Am Soc Nephrol. 1999;10:1466–1477.
   PubMed Web of Science ®Google Scholar
• Humphreys MH. Human immunodeficiency virus-associated glomerulosclerosis. Kidney Int. 1995;48(2):311–320.
   Web of Science ®Google Scholar
• Shukla RR, Kuman A, Kimmel PL. Tranforming growth factor beta increases the expression of HIV-1 gene in transfected human mesangial cells. Kidney Int. 1993;44:1022–1029.
   PubMed Web of Science ®Google Scholar
• Bourgoignie JJ, Meneses R, Ortiz C, Jaffe D, Pardo V. The clinical spectrum of renal disease associated with human immunodeficiency virus. Am J Kidney Dis. 1988;12:131–137.
   PubMed Web of Science ®Google Scholar
• Tesar V Masek Z, Rychlik I, et al. Cytokines and adhesion molecules in renal vasculitis and lupus nephritis. Nephrol Dial Transplant. 1998;13(7):1662–1667.
   PubMed Web of Science ®Google Scholar
• Arimura Y, Minoshima S, Kamiya Y, et al. Serum myeloperoxidase and serum cytokines in anti-myeloperoxidase antibody associated glomerulonephritis. Clin Nephrol. 1993;40:256–265.
   PubMed Web of Science ®Google Scholar
• Ooi J, Phoon RKS, Holdsworth SR, Kitching R. IL-23, not IL-12, directs autoimmunity to the Goodpasture antigen. J Am Soc Nephrol. 2009;20:980–989.
   PubMed Web of Science ®Google Scholar
• Dean EG, Wilson GR, Li M, et al. Experimental autoimmune Goodpasture’s disease: a pathogenetic role for both effector cells and antibody in injury. Kidney Int. 2005;67:566–575.
   Web of Science ®Google Scholar
• Annunziato F, Cosmi L, Santarlasci V et al. Phenotypic and functional features of human Th17 cells. J Exp Med. 2007;204(8):1849–1861.
   PubMed Web of Science ®Google Scholar
• Timoshanko JR, Kitching R, Holdsworth SR, Tipping PG. Interleukin-12 from intrinsic cells is an effector of renal injury in crescentic glomerulonephritis. J Am Soc Nephrol. 2001;12:464–471.
   PubMed Web of Science ®Google Scholar
• Atkins R, Nikolic-Paterson DJ, Song Q, Lan HY Modulators of crescentic glomerulonephitis. J Am Soc Nephrol. 1996;7(11):2271–2278.
   Web of Science ®Google Scholar
• Pertosa G, Grandallo G, Gesualdo L, Schena FP. Clinical relevance of cytokine production in hemodialysis. Kidney Int. 2000; 58 Suppl 76:S104–S111.
   Web of Science ®Google Scholar
• Pertosa G, Gesualdo J, Bottalico D, Schena FP. Endotoxins modulate chronically tumor necrosis factor alpha and interleukin-6 release by uremic monocytes. Nephrol Dial Transplant. 1995;10:328–333.
   PubMed Web of Science ®Google Scholar
• Dinarello CA. Cytokines as endogenous pyrogens. J Infect Dis. 1999;179 Suppl 2:S294–S304.
   Web of Science ®Google Scholar
• Hammond EA, Smart D, Toulmond S, Suman-Chauhan N, Hughes J, Hall MD. The interleukin-1 type I receptor is expressed in human hypothalamus. Brain. 1999;122:1697–1707.
   PubMed Web of Science ®Google Scholar
• Takahashi S, Kapas L, Fang J, Krueger JM. Somnogenic relationships between tumor necrosis factor and interleukin-1. Am J Physiol. 1999;276:R1132–R1140.
   Google Scholar
• Monier-Faugere MC, Malluche HH. Role of cytokines in renal osteodystrophy. Curr Opin Nephrol Hypertens. 1997;6:327–332.
   Web of Science ®Google Scholar
• Tani-Ishii N, Tsunoda A, Teranaka T, Umemoto T. Autocrine regulation of osteoclast formation and bone resorption by IL-1,TNF-a. J Dent Res. 1999;78(10):1617–1623.
   Web of Science ®Google Scholar
• Kaizu Y, Kimura M, Yoneyama T, Miyagi K, Hibi I, Kumagai H. Interleukin-6 may mediate malnutrition in chronic hemodialysis patients. Am J Kidney Dis. 1998;31:93–100.
   PubMed Web of Science ®Google Scholar
• Pertosa G, Grandaliano G, Gesualdo L, Ranieri E, Monno R, Schen FP Interleukin-6, interleukin-8, and monocyte chemotactic peptid-1 gene expression and protein synthesis are independently modulated by hemodialysis membranes. Kidney Int. 1998;54:570–579.
   PubMed Web of Science ®Google Scholar
• Hasuike Y, Nonoguchi H, Ito K, et al. Interleukin-6 is a predictor of mortality in stable hemodialysis patients. Am J Nephrol. 2009;30(4):389–398.
   Web of Science ®Google Scholar